Diagnosis of Renal Osteodystrophy Among Chronic Kidney Disease Patients
|
|
- Berenice Short
- 6 years ago
- Views:
Transcription
1 Diagnosis of Renal Osteodystrophy Among Chronic Kidney Disease Patients Samina S. Khan, MD, MPH, MBA; Mohammad R. Iraniha, MD Dr. Khan is an Assistant Professor of Medicine and Dr. Iraniha is a Research Associate at Tufts University School of Medicine, Boston, Massachusetts. OBJECTIVE: The purpose of this review was to study the prevalence of and establish an association between biochemical markers and the underlying rate of bone turnover in renal osteodystrophy. METHODS: Using the PubMed database, we undertook a systematic review of literature using studies that included bone histology in combination with serum biochemical markers among chronic kidney disease (CKD) patients, published between 1985 and Studies having at least 3 of 7 serum biochemical markers were chosen for this review. RESULTS: Of the dialysis patients who were recipients of 1,701 bone biopsies, 41% had hyperparathyroid bone disease, 5% had osteomalacia, and 33% had adynamic bone disease. Among CKD patients not on dialysis, of a total of 1,316 bone biopsies, 34% had hyperparathyroid bone disease, 19% had osteomalacia, and 8% had adynamic bone disease. Dialysis patients who had high-turnover bone disease compared with those with low bone turnover had signifi cantly higher levels of parathyroid hormone, serum alkaline phosphatase, bone-specifi c alkaline phosphatase, and osteocalcin. A similar relationship was observed among CKD patients not on dialysis. There was signifi cant individual variation in bone turnover biochemical markers. CONCLUSIONS: A combination of serum biochemical markers might predict underlying renal osteodystrophy better than would individual biochemical markers. A predictive model using bone histology and biochemical markers can be developed in the future. The overall prevalence of chronic kidney disease (CKD) in the adult population in the United States is 16.8%. 1 CKD is associated with multiple complications, and renal osteodystrophy (ROD) is significant among them. 2 Secondary hyperparathyroidism (SHPT) is an accompaniment of ROD, resulting from disturbances in the regulation of parathyroid hormone (PTH), calcium (Ca), phosphorus (P), and vitamin D. Levels of vitamin D begin to decrease as early as CKD stage 2, and simultaneously PTH levels begin to increase. 3 As CKD progresses, serum levels of phosphate increase, whereas serum levels of calcium decrease, 4 which serves as a stimulus to PTH secretion. Hyperphosphatemia seems to be an important risk factor for the development of SHPT; however, SHPT can occur during stage 3 of kidney failure, before the development of hyperphosphatemia. 4,5 Impaired calcitriol synthesis is one of the major factors contributing to the development of secondary hyperparathyroidism in patients with CKD. 4 ROD is associated with high morbidity and mortality, 6-8 as patients with end-stage kidney disease (ESKD) are at increased risk of bone loss and hip fracture. 9,10 The incidence of fracture in ESKD is reported to be 1% per year for the hip and about 2.6% for any other fracture, 11,12 although the incidence of hip fracture in the general population is only 0.07% 0.22%. 13 Duration of kidney replacement therapy, history of kidney transplant, exposure to glucocorticoids, and both very high and low levels of parathyroid hormone (PTH), in addition to general risk factors like older age, female sex, low body weight, postmenopausal status, osteoporosis history, and family history of osteoporosis or history of previous fracture, are among the significant risk factors. 14 The quality of life in patients with ROD is primarily affected by musculoskeletal problems such as bone pain, muscle weakness, growth retardation, and skeletal deformity. 15 œ TABLE I. Overall histological distribution of ROD among dialysis patients. Studies (n) Biopsies (n) ABD OM Normal MOD SHPT (33%) 91 (5%) 89 (5%) 230 (13.5%) 698 (41%) ROD, renal osteodystrophy; ABD, adynamic bone disease; OM, osteomalacia; MOD, mixed osteodystrophy; SHPT, secondary hyperparathyroid bone disease. February 2009 Dialysis & Transplantation 1
2 Renal Osteodystrophy in CKD Patients ROD among CKD patients can be the result of either increased bone turnover, decreased bone turnover, or a mixture of both. ROD is broadly classified into: osteitis fibrosa (OF), osteomalacia (OM), adynamic bone disease (ABD), and mixed osteodystrophy (MOD). 16 Although patients with a mild to moderate degree of CKD rarely experience symptoms, these skeletal changes develop years before symptoms arise. 17 As therapy for ROD varies, it is essential to establish the underlying diagnosis before assigning appropriate treatment. At present, bone biopsy is the gold standard for diagnosis of ROD; however, because of its invasive nature and overall complexity, clinicians rely on serum PTH levels for the TABLE II. Histological distribution of ROD among dialysis patients in individual studies. References Biopsies (n) ABD OM Normal MOD SHPT Chazan et al., 57 3 (5.3%) 16 (28.1%) 15 (26.3%) 23 (40.3%) DeVita et al., 20 N/A N/A Aluminum associated: 2; osteoporosis: 1 5 (1 associated osteomalacia) 11 HPT; 1 OM HPT Hercz et al., % 4.2% Mild 17.7% 6.2% 22.5% Goodman et al., PD N/A N/A 3 mild N/A 11 (78.6%) Torres et al., HD: 49; CAPD: 32 Ureña et al., HD 32% CAPD 48% N/A N/A N/A HD: 32%; CAPD: 14% (23.8%) N/A N/A N/A 32 (76.2%) Fletcher et al., 73 3 (4%) Coen et al., (22.0%) N/A N/A 9 (22.0%) 23 (56.0%) Forerol et al., (2.9%) 20 mild 2 (2.9%) 31 (44.3%) Olaizola et al., 20 8 (40%) N/A 5 mild (25%) 7 (35%) Haese et al., (35%) 10 (10%) 13 (13%) 21 (21%) 21 (21%) Gerakis et al., (3.2%) 6 (9.7%) 40 (64.5%) Sanchez et al., N/A 16 mild N/A 5 (8.8%) Jarava et al., (28%) 2 N/A 5 Mild: 8; OF: Pecovnik Balon & 30 5 (16%) N/A N/A 15 OF 10 Bren, Changsirikulchai et (41.1%) 2 (3.6%) 3 (5.4%) 11 (19.6%) 16 (28.6%) al., Ballanti et al., 37 5 (13.5%) 7 (18.9%) 4 mild (10.8%) 5 (13.5%) 16 (43.3%) Marie et al., LBT: 28 N/A N/A N/A HTO or normal: 23 Coen et al., (20.5%) 2 (5.1%) N/A 17 (43.6%) 12 (30.8%) Continued 2 Dialysis & Transplantation February 2009
3 TABLE II. (Continued) References Biopsies (n) ABD OM Normal MOD SHPT Chu et al., (28.6%) 1 (7.1%) N/A 3 (21.4%) 6 (42.9%) Ng et al., % 10% 12% mild 8% 21% Gal-Moscovici & Popovtzer, % 13% 21% 40% Coen et al., LTO: 14; adynamic: 7 N/A 1 normal Coen et al., 38 3 (7.9%) 3 (7.9%) N/A 11 (28.9%) 21 (55.3%) Van Eps et al., N/A LTO 4 3 (17.7%) N/A HTO: 10 Barreto et al., (58%) 1 (1%) 3 (3%) 24 (25%) 12 (12%) HD, hemodialysis; PD, peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; LTO, low turnover; HTO, high turnover; N/A, not applicable or not available. diagnosis and treatment of ROD among CKD patients. The purpose of our systematic review was to study the prevalence of and evaluate an association between serum biochemical markers such as Ca, P, PTH, alkaline phosphatase (ALP), bone specific alkaline phosphatase (bsalp), osteocalcin (OC) or vitamin D, and bone histology in order to predict a diagnosis of ROD. Methods Using the PubMed database, we undertook a systematic review of the literature for studies describing the distribution of ROD among CKD patients on dialysis and CKD patients not on dialysis [search 1: kidney failure, chronic (MeSH) AND renal osteodystrophy (MeSH); search 2: renal osteodystrohy (MeSH) and biochemical markers; search 3: kidney failure, chronic (MeSH) AND biochemical markers AND bone histomorphometry; search 4: dialysis (MeSH) AND biochemical markers AND bone histology]. Of all the retrieved results, we selected articles published between 1985 and 2007 that provided information on bone histology in combination with serum biochemical markers of patients with CKD. Of the 42 articles we reviewed, 3 were in Spanish, 1 was in Japanese, and the rest were in English. Of these 42 articles, we selected 13 studies that had at least 3 of these 7 serum biochemical markers: PTH, Ca, P, ALP, bsalp, OC, and vitamin D. Because serum biochemical markers were expressed either as mean standard deviation (SD) or standard error (SE), we converted SE to SD by using the formula SE SD/ n. A weighted average of the mean and SD were calculated. To calculate the mean, we multiplied the number of patients in each category by the means of the serum biochemical markers and divided by the total number of patients in the study. To calculate the weighted standard deviation, the second power of each standard deviation was added, and then the square root of the sum was taken. We divided patients into those with high-turnover (HTO) bone disease and those with low-turnover (LTO) bone disease, according to bone histology. All patients with mixed bone disease, mild, moderate, or severe hyperparathyroidism, and OF cystica were included in the highturnover group, whereas patients with ABD and OM were included in the low-turnover group. If there were several categories in each histological type such as mild, moderate, and severe hyperparathyroidism, we calculated the weighted average for serum biochemical markers in each category. Results We reviewed 42 articles, of which 26 included dialysis patients and 16 included CKD patients not on dialysis. Table I summarizes the overall histological distribution of ROD among dialysis patients. Of the patients receiving 1,701 bone biopsies, 41% had hyperparathyroidism, 5% OM, and 33% ABD. The rest were classified as normal bone or mixed bone disease. There was variability among studies in reporting bone histology. Some studies did not report the histological types of all biopsies, and 1 study reported 17 patients with OM among 33 with SHPT. Table II summarizes the histological distribution of ROD among dialysis patients in individual studies. The presence of ABD significantly varied in each study, ranging from 4% to 63%. Table III summarizes the histological distribution of ROD among CKD patients not on dialysis. Of these patients who received 1,316 bone biopsies, 34% had hyperparathyroidism, 19% OM, and 8% ABD. Table IV summarizes the histological distribution of ROD among CKD patients not on dialysis TABLE III. Histological distribution of ROD among CKD patients not on dialysis. Studies (n) Biopsies (n) (8%) ABD OM Normal MOD SHPT 255 (19%) 269 (20%) 244 (18%) 453 (34%) œ February 2009 Dialysis & Transplantation 3
4 Renal Osteodystrophy in CKD Patients TABLE IV. Histological distribution of ROD among CKD patients not on dialysis in individual studies. References Biopsies (n) ABD OM Normal MOD SHPT Mora et al., N/A OM with OF: 112 Lindenau et al., CKD: mild 53, moderate 40, advanced 44 N/A CKD: mild 12, moderate 3, advanced 4 Neither OM or OF: 40 CKD: mild 5, moderate 9, advanced 5 N/A OF alone: 175 CKD: mild 24, moderate 21, advanced 29 CKD: mild 12, moderate 7, advanced 6 Sellares et al., N/A 7 (13.2%) 1 (1.9%) 7 (13.2%) Severe: 12; mild: 26 Hutchison et al., 30 8 (27%) 2 (7%) 1 (3%) 4 (13%) OF: Sato, N/A 4 (6.5%) N/A N/A OF: 1; mild: 57 Hamdy et al., (5.1%) With HPT: 24; 44 (25%) N/A 98 (55.7%) OM alone: 1 Coen et al., (11.8%) 7 (9.2%) 10 (13.2%) MOD: mild 26, advanced 22 2 HP (2.6%) Lafage et al., (25%) 2 (12.5%) 7 (43.7%) N/A 3 OF Ballanti et al., (22.2%) 3 (11.1%) N/A MOD: advanced 9, mild 7 2 (7.4%) Coen et al., (11.4%) 8 (10.1%) 10 (12.6%) 50 (63.3%) 2 (2.5%) Duothat et al., (9.6%) 10 (19.2%) N/A 10 (19.2%) Severe: 13; mild: 14 Spazovski et al., 84 23% 12% 38% 18% 9% mild Bervoets et al., (22.6%) 10 (11.9%) 32 (38.1%) 15 (17.9%) 8 (9.5%) Lobao et al., (low densitometry) 52.5% 42.5% N/A 5% N/A Lehmann et al., Stages 3/4: 35 Stages 3/4: 3 (8.6%) Stages 3/4: 2 (5.7%) Stages 3/4: 7 normal, 4 mild Stages 3/4: 3 (8.6%) Stages 3/4: OF 16 (45.7%) in the individual studies. The presence of ABD significantly varied in each study, ranging from 5.1% to 27%. Table V presents serum biochemical markers in dialysis patients with ROD (LTO versus HTO). There were a total of 221 patients in the low-turnover and 303 in the high-turnover group. When compared with the LTO group, patients with HTO bone disease had significantly higher levels of ALP, bsalp, OC, and ipth. There was no significant difference between 2 groups in terms of Ca and P. Table VI presents biochemical markers in CKD patients not on dialysis with ROD (LTO versus HTO). There were a total of 78 patients in the LTO group and 29 patients in the HTO group. When compared with the LTO bone disease group, patients with HTO bone disease had significantly higher bsalp, 4 Dialysis & Transplantation February 2009 OC, and ipth. The level of Ca, P, and ALP were not significantly different between the 2 groups. Figure 1 shows the comparison of histological variations in ROD between dialysis patients and CKD patients not on dialysis. ABD is more common in dialysis patients than in CKD patients not on dialysis. Figures 2 and 3 show a comparison of all serum biochemical markers in dialysis and CKD patients not on dialysis with LTO and HTO bone disease, respectively. Discussion ROD comprises a wide spectrum of manifestations that includes a high-turnover state such as hyperparathyroid bone disease and a low-turnover state such as OM and ABD. 18 ROD occurs early in the course of CKD and worsens as kidney function declines. Bone disease is common among patients with CKD stage 5, and by the time dialysis is initiated, almost all patients are affected. 19 Our goal was to evaluate the prevalence of ROD and establish an association between serum biochemical markers associated with the rate of bone turnover such as PTH, ALP, bsalp, or OC, with underlying bone histology, in order to establish an accurate diagnosis of ROD, which is essential to assign treatment. We found an overall high prevalence of adynamic bone disease 33% and 8% among CKD patients on dialysis and CKD patients not on dialysis, respectively. However, individual studies have found a prevalence of adynamic disease as high as 58% and 52% among dialysis patients and CKD
5 TABLE V. Biochemical markers in dialysis patients with ROD (low turnover versus high turnover). References Patients (n) Ca (mg/dl) P (mg/dl) AP (IU/L) bsalp OC ( g/l) Low turnover Hercz et al., N/A N/A N/A 77 Urena et al., N/A N/A Fletcher et al., N/A N/A Coen et al., N/A N/A N/A Gerakis et al., (54 140) N/A N/A N/A 15 (4 37) Jarava et al., N/A Monier et al., N/A N/A Coen et al., N/A Total (n) 221 Mean SD High turnover Hercz et al., N/A N/A N/A Ureña et al., N/A N/A Fletcher et al., N/A N/A Coen et al., N/A N/A N/A Gerakis et al., (95 430) N/A N/A N/A 714 ( ) Jarava et al., N/A N/A Monier et al., N/A N/A 530 Coen et al., N/A Total (n) 303 Mean SD Vit D ipth patients not on dialysis, respectively. We found hyperparathyroid bone disease was the most common type of ROD in both CKD patients on dialysis and those not on dialysis. In the dialysis group, PTH, ALP, bsalp, and OC were significantly higher in those with HTO bone disease than in those with LTO bone disease. Similarly, in CKD patients not on dialysis, PTH, bsalp, and OC were significantly higher in those with HTO bone disease than in those with LTO bone disease. Various methods such as serum biochemical markers, imaging studies, and histopathological studies are currently used to diagnose ROD. Ca, P, PTH, ALP, and bsalp are among the most commonly used serum biochemical markers. Similar to previous studies, we found no significant association between serum Ca or P with rate of bone turnover in ROD. 20,21 PTH is most commonly used as a serum biochemical marker to determine the underlying bone disease in CKD patients. Biologically active PTH circulates mostly as a 1 84 amino-acid peptide. 22 PTH fragments containing carboxy-terminal parts of the molecule of varying length are also present in circulation. First-generation immunoradiometric assays of so-called intact PTH not only measured full-length PTH (1 84) but also recognized large PTH fragments lacking the amino terminus The Nichols assay for the estimation of intact parathyroid hormone (i-pth) overestimates parathyroid gland function by recognizing both the whole PTH-1-84 molecule (identified as a cyclase-activating PTH-CAP) and N-truncated fragments of PTH-7-84 (identified as a cyclase-inactive PTH-CIP). 24 Currently, a third-generation assay, which measures 1-84 PTH, and whole PTH and provides 7-84 PTH, 25 manufactured by Scantibodies (San Clemente, Calif.), and the ratio of 1-84/7-84 has shown to be associated with rate of bone turnover. 26 Serum levels of PTH can predict the presence and severity of SHPT without correlating with the underlying bone disease. 24,27 Levels of ipth in dialysis patients œ February 2009 Dialysis & Transplantation 5
6 Renal Osteodystrophy in CKD Patients TABLE VI. Biochemical markers in CKD patients not on dialysis with ROD (low turnover versus high turnover). References Patients (n) Ca (mg/ dl) P (mg/dl) ALP (IU/L) bsalp OC ( g/l) Vit D ipth Low turnover Hutchison et al., N/A N/A Coen et al., N/A N/A N/A Coen et al., N/A Coen et al., 17 N/A N/A N/A N/A Spasovski et N/A al., Total (n) 78 Mean SD High turnover Hutchison et al., N/A N/A Coen et al., ( ) 7.3 ( ) (78 225) N/A N/A N/A 897 ( ) Coen et al., N/A Coen et al., 2 N/A N/A (78 225) N/A N/A 23 (18 28) ( ) Spasovski et ( ) 6.3 ( ) 91 (50 223) 42 (20 126) 76 (11 183) N/A 201 ( ) al., Total (n) 29 Mean SD bsalp, bone-specifi c alkaline phosphatase; OC, osteocalcin. more than 4 times normal and less than 2 times normal are associated with a greater frequency of HTO and LTO bone disease, respectively. 28 Although PTH is a good indicator of bone metabolism, the sensitivity and specificity to diagnose HTO bone disease with levels <500 ng/ml and ABD disease with levels <100 ng/ml are inadequate. 28 Bone biopsy studies among dialysis patients revealed that bone remodeling and response to PTH varies among various racial groups. 29,30 In a study of 76 ESKD patients, the majority of African American patients with LTO bone disease had higher serum PTH levels than those of whites with LTO bone disease. 29 In our systematic review, although individual patients had variations in the correlation of PTH with underlying bone turnover, at an aggregate level there was a good correlation between the level of PTH and bone turnover among both dialysis and non-dialysis patients. ALP is a marker of osteoblast-mediated bone formation that does provide useful information in conjunction with PTH measurement. 31 The combination of low serum bsalp ( 7 ng/ml) and low serum PTH is very suggestive of LTO bone disease. 32 Similarly, an elevated bsalp (>200 ng/ml) alone or in combination with increased serum PTH (>200 ng/ml) has been shown to be highly sensitive and specific for HTO bone disease. 33 Although bsalp may provide some advantage, some experts believe that total serum ALP plus PTH levels are adequate to evaluate bone formation. 18 In our review, we found good correlation between serum ALP and bone turnover among dialysis patients; however, such correlation was not present among CKD patients not on dialysis. Bone-specific ALP, a more specific 6 Dialysis & Transplantation February 2009
7 FIGURE 1. Comparison of ROD distribution among dialysis patients and CKD patients not on dialysis. FIGURE 2. Comparison of serum biochemical markers in dialysis patients with low- and high-turnover bone disease. FIGURE 3. Comparison of serum biochemical markers in CKD patients not on dialysis with lowand high-turnover bone disease. indicator of osteoblastic activity, was not reported in all articles used in our review. However, based on our data, there was a good correlation between bsalp and bone turnover. In dialysis patients with HTO bone disease, the levels of bsalp were almost 4 times higher than those in LTO bone disease. Similarly, in CKD patients not on dialysis with HTO bone disease, the levels of bsalp were almost double than those in LTO bone disease. The serum level of OC an indicator of bone formation reflects the rate of OC synthesis by osteoblasts. Among biomarkers, which reflect bone formation, the OC assay is preferred because of its high discriminant power and is better characterized in terms of clinical application. 34 In our review, OC was reported in a limited number of articles; however, using the aggregate data, there was a good correlation between level of OC and bone turnover. Among dialysis patients with HTO bone disease, OC levels were almost 3 times greater than those in LTO bone disease. Similarly, in CKD patients not on dialysis with HTO bone disease, the levels of OC were almost twice those of patients with LTO bone disease. Additionally, as an indicator of osteoblastic activity, other biomarkers such as tartrate-resistant acid phosphatase, serum C-terminal telopeptide of collagen type I, and pyridinolin crosslinks as indicators of the resorption process can be specifically measured to estimate bone turnover and are important for noninvasive diagnosis of ROD. 35,36 Radiographic examination of bone can provide important information regarding the presence of hyperparathyroidism such as osteopenia, subperiosteal resorption, and cysts. However, radiological finding are less sensitive and do not determine renal osteodystrophy. Among patients with advance bone disease, plain films may reveal subperiosteal resorption in severe OF or looser zones in severe OM. 18 The importance of bone mineral density (BMD) measurement is unclear in patients with ROD; however, a lower BMD has shown to predict fracture risk in dialysis patients. 37,38 In CKD patients, distal radius is the preferred site for BMD measurement, as BMD of the spine may be misleading because of aortic calcifications. The prevalence of osteopenia and/or osteoporosis also increases with a decreasing glomerular filtration rate. 39 In a study of patients with CKD, the highest levels of BMD in the lumbar spine, hip, and distal forearm were found in those with a glomerular filtration rate between 70 and 110 ml/min/1.73 m 2 (stages 1 and 2 CKD), whereas those with a glomerular filtration rate between 6 and 26 ml/min/1.73 m 2 (stage 4 CKD) had the lowest BMD levels. The abnormalities in bone metabolism that might be responsible for the decreased BMD were not characterized in these studies. The presence of osteoporosis œ February 2009 Dialysis & Transplantation 7
8 Renal Osteodystrophy in CKD Patients is a strong predictor of increased risk for fractures in the general population. Although the importance of BMD and risk reduction in fractures by treatment of osteoporosis has not been established among CKD patients, serial measurement of BMD using dual energy x-ray absorptiometry can identify patients with a continuous decline in BMD and increased risk of fractures. A combination of serum biochemical markers can predict the underlying rate of bone turnover with more accuracy. A study of 30 chronic hemodialysis patients in whom a bone biopsy was performed in conjunction with assessment of biochemical markers showed that if only PTH was taken into consideration, 36.6% of patients were correctly classified according to their diagnosis. However, if both PTH and bone densitometry were taken into consideration, 46.6% were classified correctly. Considering PTH and radiological changes in clavicular and metacarpal bones such as periosteal, endosteal, and intracortical resorption, 60% of patients were classified correctly. 40 In conclusion, we found that on a collective basis serum levels of PTH, AP, bsalp, and osteocalcin are high in highturnover bone disease and low in low-turnover bone disease. Use of a combination of 3 or more markers may determine underlying renal osteodystrophy with more accuracy than individual biochemical markers. However, a bone biopsy should be encouraged in younger patients with ESKD, with PTH levels between 200 and 500 pg/dl, where other biochemical markers are not well defined. Limitations Similar to any systematic review, lack of individual patient data, variability in histological classification within studies, and lack of use or reporting of all biochemical markers were limitations of our review. Conclusions The most common histological type of ROD among dialysis and CKD patients not on dialysis was hyperparathyroid bone disease; however, the presence of adynamic bone disease was significant in both groups. 8 Dialysis & Transplantation February 2009 A combination of 2 or 3 serum biochemical markers such as PTH, ALP, bsalp, and OC might help clinicians to more accurately diagnose ROD in order to assign treatment with vitamin D. D&T References 1. Prevalence of chronic kidney disease and associated risk factors United States, MMWR Morb Mortal Wkly Rep. 2007;56: Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008;35: Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial. 2005;18: Sanchez CP, Goodman WG, Salusky IB. Prevention of renal osteodystrophy in predialysis patients. Am J Med Sci. 1999;317: González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insuffi ciency and defi ciency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004;24: Coburn JW, Norris KC, Nebeker HG. Osteomalacia and bone disease arising from aluminum. Semin Nephrol. 1986;6: Gabriel R. Morbidity and mortality of long-term haemodialysis: a review. J R Soc Med. 1984;77: Piraino BM, Rault R, Dominguez JH, Puschett JB. Renal osteodystrophy in patients on hemodialysis for more than 10 years. Miner Electrolyte Metab. 1986;12: Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis. 2004;44: Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008;74: Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58: Ball AM, Gilllen DL, Sherrard DJ, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002;288: Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17: Stehman-Breen CO, Sherrard DJ, Alem AM, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58: Tejwani NC, Schachter AK, Immerman I, Achan P. Renal osteodystrophy. J Am Acad Orthop Surg. 2006;14: Ritz E, Merke DJ, Lukas PA. Genesis of bone disease in uremia. In: Peck WA, ed. Bone in Mineral Research. 5th ed. Amsterdam, The Netherlands: Elsevier; 1987: Hamdy NA, Kanis JA, Beneton MN, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310: Moe S, Drüeke T, Cunningham, J, et al. Defi nition, evaluation, and classifi cation of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69: Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36: DeVita MV, Rasenas LL, Bansal M, et al. Assessment of renal osteodystrophy in hemodialysis patients. Medicine (Baltimore). 1992;71: Fletcher S, Jones RG, Rayner HC, et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron. 1997;75: Jüppner H, Potts Jr JT. Immunoassays for the detection of parathyroid hormone. J Bone Miner Res. 2002;17(Suppl 2):N81-N Friedman PA. PTH revisited. Kidney Int Suppl. 2004;91:S13-S Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004;43: Souberbielle JC, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta. 2006;366: Negri AL, Alvarez Quiroga M, Bravo M, et al. [Whole PTH and 1-84/84 PTH ratio for the non invasive determination of low bone turnover in renal osteodysthrophy]. Nefrologia. 2003;23: Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol. 2005;63: K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Available at: Sawaya BP, Butros R, Naqvi S, et al. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int. 2003;64: Sawaya BP, Monier-Faugere MC, Ratanapanichkich P, et al. Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol. 2002;57: Sprague SM. The role of the bone biopsy in the diagnosis of renal osteodystrophy. Semin Dial. 2000;13: Urena P, De Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999;55: Ureña P, Hruby M, Ferreira A, et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7: Taylor AK, Leuken SA, Libanati C, Baylink DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am. 1994;20: Mazzaferro S, Pasquali M, Ballanti P, et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant. 1995;10: Ureña P, Ferreira A, Kung VT, et al. Serum pyridinoline as a specifi c marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res. 1995;10: Yamaguchi T, Kanno E, Tsubota J, et al. Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures. Bone. 1996;19:
9 38. Ureã P, Bernard-Poenaru O, Ostertag A, et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant. 2003;18: Rix M, Andreassen H, Eskilden P, Langdahl B, Olgaard K, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999;56: Pecovnik Balon B, Bren A. Bone histomorphometry is still the golden standard for diagnosing renal osteodystrophy. Clin Nephrol. 2000;54: Chazan JA, Libbey NP, London MR, et al. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology fi ndings. Clin Nephrol. 1991;35: Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: the role of suppressed parathyroid function. Kidney Int. 1993;44: Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994;46: Torres A, Lorenzo V, Hernández D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int. 1995;47: Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant. 1998;13: Velasquez Forero F, Altamirano E, Ramos PT. High frequency of iron bone deposits in a Mexican population with renal osteodystrophy. Nephrol Dial Transplant. 1998;13(Suppl 3): Olaizola I, Aznarez A, Jorgetti V, et al. Are there any differences in the parathyroid response in the different types of renal osteodystrophy? Nephrol Dial Transplant. 1998;13(Suppl 3): D Haese PC, Couttenye MM, Lamberts LV, et al. Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. Clin Chem. 1999;45: Gerakis A, Hadjidakis D, Kokkinakis E, et al. Correlation of bone mineral density with the histological fi ndings of renal osteodystrophy in patients on hemodialysis. J Nephrol. 2000;13: Carmen Sánchez M, et al. Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis. 2000;36: Jarava C, Armas JR, Palma A. [Study of renal osteodystrophy by bone biopsy. Age as an independent factor. Diagnostic value of bone remodeling markers]. Nefrologia. 2000;20: Changsirikulchai S, Domrongkitchaiporn S, Sirikulchayanonta V, et al. Renal osteodystrophy in Ramathibodi Hospital: histomorphometry and clinical correlation. J Med Assoc Thai. 2000;83: Ballanti P, Coen G, Mazzaferro S, et al. Histomorphometric assessment of bone turnover in uraemic patients: comparison between activation frequency and bone formation rate. Histopathology. 2001;38: Monier-Faugere MC, Geng Z, Mawad H, et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60: Coen G, Ballanti P, Balducci A, et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant. 2002;17: Chu P, Chao TY, Lin YF, et al. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis. 2003;41: Ng AH, Hercz G, Kandel R, Grynpas MD. Association between fl uoride, magnesium, aluminum and bone quality in renal osteodystrophy. Bone. 2004;34: Coen G, Mantella D, Manni M, et al. 25-Hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int. 2005;68: Coen G, Ballanti P, Balducci A, et al. Renal osteodystrophy: alpha-heremans Schmid glycoprotein/fetuin-a, matrix GLA protein serum levels, and bone histomorphometry. Am J Kidney Dis. 2006;48: Van Eps CL, Jeffries JK, Anderson JA, et al. Mineral metabolism, bone histomorphometry and vascular calcifi cation in alternate night nocturnal haemodialysis. Nephrology (Carlton). 2007;12: Barreto FC, Barreto DV, Moysés RM, et al. K/DOQIrecommended intact PTH levels do not prevent lowturnover bone disease in hemodialysis patients. Kidney Int. 2008;73: Mora Palma FJ, Ellis HA, Cook DB, et al. Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med. 1983;52: Lindenau K, Kokot F, Vetter K, et al. Current status of diagnosis and treatment of renal osteodystrophy in the predialysis period. Contrib Nephrol. 1988; Lorenzo Sellares V, Torres Ramírez A, Hernández Marrero D, et al. [A study using nondecalcifi ed bone biopsy of the incidence and presentation forms of renal osteodystrophy]. Med Clin (Barc). 1991;96: Hutchison AJ, Whitehouse RW, Boulton HF, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993;44: Sato T. [Studies on the pathogenesis and pathophysiology of renal osteodystrophy. II. Bone histology of chronic renal failure patients at the time of starting hemodialysis]. Nippon Jinzo Gakkai Shi. 1994;36: Coen G, Mazzaferro S, Ballanti P, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant. 1996;11: Lafage-Proust MH, Combe C, Barthe N, Aparicio M. Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction. J Clin Endocrinol Metab. 1999;84: Coen G, Ballanti P, Bonucci E, et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002;91: Douthat WG, Garay G, de Arteaga J, et al. [Biochemical and histological spectrum of renal osteodystrophy in Argentina]. Nefrologia. 2003;23(Suppl 2): Spasovski GB, Bervoets AR, Behets GJ, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003;18: Bervoets AR, Spasovski GB, Behets GJ, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003;41: Lobão R, Carvalho AB, Cuppari L, et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol. 2004;62: Lehmann G, Stein G, Hüller M, et al. Specifi c measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int. 2005;68: February 2009 Dialysis & Transplantation 9
PART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 23, 2007 Alicja E. Grzegorzewska, Monika Mĺot Michalska Serum Level of Intact Parathyroid Hormone and Other Markers of Bone Metabolism
More informationCKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire
Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School
More informationK/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients
http://www.kidney-international.org & 2008 International Society of Nephrology original article see commentary on page 674 K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease
More informationIntroduction/objective: Adinamic bone disease (ABD) is a common finding in peritoneal. dialysis (PD) and is associated with a
Original Article Low-calcium peritoneal dialysis solution is effective in bringing PTH levels to the range recommended by current guidelines in patients with PTH levels < 150 pg/dl Authors Thyago Proença
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationReversal of adynamic bone disease by lowering of dialysate calcium
http://www.kidney-international.org & 26 International Society of Nephrology original article Reversal of adynamic bone disease by lowering of dialysate calcium A Haris 1, DJ Sherrard 2 and G Hercz 3 1
More informationAdvances in Peritoneal Dialysis, Vol. 22, 2006
Advances in Peritoneal Dialysis, Vol. 22, 2006 M. Carmen Sánchez González, 1 Fernando López Barea, 2 M. Auxiliadora Bajo, 1 Rafael Selgas, 1 for the Collaborators of the Multicenter Study Group* Serum
More informationOPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura
www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationNuclear Chromatin-concentrated Osteoblasts in Renal Bone Diseases
tap_919 9..13 Therapeutic Apheresis and Dialysis 15(Supplement 1):9 13 doi: 1.1111/j.1744-9987.211.919.x Therapeutic Apheresis and Dialysis 211 International Society for Apheresis Nuclear Chromatin-concentrated
More informationManagement of mineral and bone disorders in renal transplant recipients
Nephrology 22, Suppl. 2 (2017) 65 69 Management of mineral and bone disorders in renal transplant recipients MATTHEW J DAMASIEWICZ 1,3 and PETER R EBELING 2,3,4 Departments of 1 Nephrology, and 2 Endocrinology,
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationJemds.com. Original Article STUDY OF RENAL OSTEODYSTROPHY IN CHRONIC RENAL FAILURE
STUDY OF RENAL OSTEODYSTROPHY IN CHRONIC RENAL FAILURE Nalina Thimmappa 1, Giriraja Kanakapura Vrushabaih 2, Pula Laxmi Bindumathi 3, Pooja Pillai 4, Bhaskar Balasundaram 5 1Associate Professor, Department
More informationPREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL
PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL DR. ANNE MUGERA The Problem Chronic Kidney disease is a worldwide
More informationDifferences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease
Kidney International, Vol. 64 (2003), pp. 737 742 Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease B. PETER SAWAYA, REZKALLA
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More information... . : ... PTH.
IRMA Email msarookhani@qumsacir * CRD GFR D [1,25OH 2 D 3 ] SHPT GFR» «KDOQI SHPT Ca * P P P Selectra Overt HPT = = Ca * P P > GM II DSL i IRMA ± ± ± Ca * P % % % % % % % % % % % % % % % % pgml = = > ±
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationComparison of the Humoral Markers of Bone Turnover and Bone Mineral Density in Patients on Haemodialysis and Continuous Ambulatory Peritoneal Dialysis
Original Paper Nephron 2002;91:94 102 Accepted: July 5, 2001 Comparison of the Humoral Markers of Bone Turnover and Bone Mineral Density in Patients on Haemodialysis and Continuous Ambulatory Peritoneal
More informationA Novel Murine Model Of Adynamic Bone Disease (ABD)
A Novel Murine Model Of Adynamic Bone Disease (ABD) Adeline H. Ng 1,2, Thomas L. Willett, PhD 2,1, Benjamin A. Alman 3,1, Marc D. Grynpas 1,2. 1 University of Toronto, Toronto, ON, Canada, 2 Samuel Lunenfeld
More informationRamzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016
Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationBone strength is proportional to bone mass, measured with DXA. Bone turnover markers indicate the status of bone quality.
Bone strength is proportional to bone mass, measured with DXA Bone quality depend on bone architecture, rate of bone turnover, quality of bone matrix. Bone turnover markers indicate the status of bone
More informationGuidelines and new evidence on CKD - MBD treatment
Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationChapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009.
http://www.kidney-international.org & 2009 KDIGO Chapter 5: Evaluation and treatment of kidney transplant bone disease ; doi:10.1038/ki.2009.193 Grade for strength of recommendation a Strength Wording
More informationMehruba Alam Ananna, Wasim Md. Mohosin Ul Haque, Muhammad Abdur Rahim, Tufayel Ahmed Chowdhury, Tabassum Samad, Md. Mostarshid Billah, Sarwar Iqbal
Original Article Correlation of serum intact parathyroid hormone and alkaline phosphatase in diabetic chronic kidney disease stage 3 to 5 patients with mineral bone disorders Mehruba Alam Ananna, Wasim
More informationFrequency of Metabolic Bone Disease in Haemodialysis Patients
Frequency of Metabolic Bone Disease in Haemodialysis Patients Pages with reference to book, From 83 To 86 Rizwan Hussain, Arshad Ahmed, Abdul Salam Soomro, Saeed Hassan Chishty, Syed Ali Jaffar Naqvi (
More informationRENAL OSTEODYSTROPHY continues to
Variant of Adynamic Bone Disease in Hemodialysis Patients: Fact or Fiction? Lillian A. Rocha, MD, Andrea Higa, MD, Fellype C. Barreto, MD, Luciene M. dos Reis, PhD, Vanda Jorgetti, MD, PhD, Sérgio A. Draibe,
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationTotal Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism
The Journal of International Medical Research 2011; 39: 978 987 Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism J NARANDA 1,2, R EKART
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationTreatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia Budapest, August 29, 2011 Session Objectives Definition of the problem of CKD-MBD
More informationRelationship of bone density with serum parathyroid hormone in hemodialysis patients; a single center study
Open Access http://www.jparathyroid.com Journal of Journal of Parathyroid Disease 2018,6(2),57 63 DOI: 10.15171/jpd.2018.19 Original Relationship of bone density with serum parathyroid hormone in hemodialysis
More informationRace Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients
J Am Soc Nephrol 11: 330 334, 2000 Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients AJAY GUPTA,* LEE R. KALLENBACH, GERARD ZASUWA,* and GEORGE W. DIVINE *Division of Nephrology
More informationBisphosphonate therapy in renal osteodystrophy a review
REVIEW DOI: 10.5301/jn.5000188 Bisphosphonate therapy in renal osteodystrophy a review Raoul Bergner Department of Internal Medicine A, Ludwigshafen General Hospital, Ludwigshafen am Rhein - Germany Abstract
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationImprovement of adynamic bone disease after renal transplantation
Brazilian Journal of Medical and Biological Research (2006) 39: 31-41 Adynamic bone disease after transplantation ISSN 0100-879X 31 Improvement of adynamic bone disease after renal transplantation K.A.
More informationHHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2013 September 01.
Choices in kidney transplantation in type 1 diabetes: Are there skeletal benefits of the endocrine pancreas? Julia J. Scialla, MD, MHS Division of Nephrology and Hypertension, Department of Medicine, University
More informationKDOQI COMMENTARY VOL 55, NO 5, MAY 2010
VOL 55, NO 5, MAY 2010 KDOQI COMMENTARY KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD Mineral and Bone Disorder (CKD-MBD) Katrin
More informationMetabolic Bone Disease (Past, Present and Future Challenges in the Management)
Metabolic Bone Disease 871 151 Metabolic Bone Disease (Past, Present and Future Challenges in the Management) SNA RIZVI INTRODUCTION The past 40 years have seen some important historical events leading
More informationNIH Public Access Author Manuscript Am J Kidney Dis. Author manuscript; available in PMC 2011 May 1.
NIH Public Access Author Manuscript Published in final edited form as: Am J Kidney Dis. 2010 May ; 55(5): 897 906. doi:10.1053/j.ajkd.2009.12.041. Intact PTH Combined With the PTH Ratio for Diagnosis of
More informationamino terminus of the hormone, detect not only PTH(1-84) Accepted for publication December 13, 2002
Kidney International, Vol. 63 (2003), pp. 1801 1808 CLINICAL NEPHROLOGY EPIDEMIOLOGY CLINICAL TRIALS Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationManagement of CKD. Goce Spasovski, R. Macedonia
Management of CKD complications Introduction Bone disease to Renagel Goce Spasovski, R. Macedonia Istanbul, June 4, 2011 Session Objectives - Mineral and Bone Disorders (MBD) Bone disease a part of CKD
More information- =>? - 1 D /" + B*
1391 5 4 2 3 2 1 8 7 6-1 -2-3 -5 ( ) -6 : -7-8 -4 :. : PTH. PTH. 1391 ( 60) :.. 1391. 150 pg/ml PTH 300 pg/ml PTH. D. ( ). D 48/13±17/35 60 : ( 35) 21. ( 53/3) 32 (46/7) 28. ( 85 11 ) ( 23,3) 14 ( 41,7)
More informationBone disease in patients with chronic kidney disease under conservative management
Bone disease in patients with chronic kidney disease under conservative management Nephrology Division, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
More informationSpectrum of renal bone disease in end-stage renal failure patients not yet on dialysis
Nephrol Dial Transplant (2003) 18: 1159 1166 DOI: 10.1093/ndt/gfg116 Original Article Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis Goce B. Spasovski 1, An R. J.
More informationTreatment Options for Chronic Kidney
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition
More informationPosttransplant Bone Disease. Budapest 2007
Posttransplant Bone Disease Budapest 2007 Post-transplant bone disease 7 10 % of kidney transplanted patients develope a fracture. The risk is higher in postmenopausal female transplanted patients. Diabetic,
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationMarie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche
Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude
More informationAssociation between Pruritus and Serum Concentrations of Parathormone, Calcium and Phosphorus in Hemodialysis Patients
Saudi J Kidney Dis Transpl 2013;24(4):702-706 2013 Saudi Center for Organ Transplantation Original Article Saudi Journal of Kidney Diseases and Transplantation Association between Pruritus and Serum Concentrations
More informationSerum markers of bone turnover in the diagnosis of renal osteodystrophy
Artigo Original Rev Port Nefrol Hipert 2005; 19 (Suppl 1): 57-71 Serum markers of bone turnover in the diagnosis of renal osteodystrophy Aníbal Ferreira Serviço de Nefrologia do Hospital Curry Cabral,
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationParathyroid Hormone: New Assays, New Receptors
Parathyroid Hormone: New Assays, New Receptors By Kevin J. Martin, Irme Akhtar, and Esther A. González Accurate measurements of parathyroid hormone (PTH) in plasma are necessary for the assessment, monitoring,
More informationAssessment of Osteoporosis Risk Factors in Low Socioeconomic Status Hemodialysis Patients in Jeddah
World Journal of Medical Sciences 1 (4): 438-443, 015 ISSN 1817-3055 IDOSI Publications, 015 DOI: 10.589/idosi.wjms.015.1.4.1154 Assessment of Osteoporosis Risk Factors in Low Socioeconomic Status Hemodialysis
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More informationTHE FIELD OF mineral metabolism and
SPECIAL REPORT Controversies in Bone and Mineral Metabolism in Chronic Kidney Disease A Bridge to Improving Healthcare Outcomes and Quality of Life Sharon M. Moe, MD, FACP, and Tilman B. Drüeke, MD, FRCP
More informationRecent advances in the noninvasive diagnosis of renal osteodystrophy
http://www.kidney-international.org & 2013 International Society of Nephrology Recent advances in the noninvasive diagnosis of renal osteodystrophy Ranjani N. Moorthi 1 and Sharon M. Moe 1,2 1 Department
More informationRenal Osteodystrophy in Pediatric Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 20, 2004 Francisco J. Cano, Marcela Valenzuela, Pedro Zambrano, Marta A. Azocar, Eduardo Wolff, Maria A. Delucchi, Eugenio E. Rodriguez Renal Osteodystrophy in Pediatric
More informationParathyroid hormone and growth in children with chronic renal failure
Kidney International, Vol. 67 (2005), pp. 2338 2345 Parathyroid hormone and growth in children with chronic renal failure SIMON C. WALLER, DEBORAH RIDOUT, TOM CANTOR, and LESLEY REES Nephro-Urology Unit,
More informationBsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients
Clinical Chemistry / BSMI POLYMORPHISM OF THE VITAMIN D RECEPTOR GENE Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients Jacopo Tagliabue, MD,1 Marco
More informationCan we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts
NDT Advance Access published July 17, 2013 Nephrol Dial Transplant (2013) 0: 1 9 doi: 10.1093/ndt/gft275 Full Review Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients?
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationAdynamic bone disease: An update and overview
REVIEW JNEPHROL 2005; 18: Adynamic bone disease: An update and overview Giorgio Coen Associate Professor of Nephrology, La Sapienza University, Nephrology and Hypertension Unit, Ospedale Israelitico, Rome
More informationThis is a repository copy of Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy.
This is a repository copy of Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/128959/
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationA clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 18, No. 6, 513 518, 2004 A clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients Seiji
More informationGUIDELINE 1. EVALUATION OF CALCIUM AND PHOSPHORUS METABOLISM
GUIDELINE 1. EVALUATION OF CALCIUM AND PHOSPHORUS METABOLISM 1.1 Serum levels of calcium, phosphorus, alkaline phosphatase, total CO 2, and PTH measured by a first-generation immunometric parathyroid hormone
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationKey words: Vitamin D analogues, alfacalcidol, calcitriol, secondary hyperparathyroidism, renal dialysis
Oral cal ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TR IAL Samantha Moe 1, Lori D Wazny 2, Janet
More informationBiochemical markers of renal osteodystrophy in pediatric
Kidney International, Vol. 45 (1994), pp. 253 258 Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD ISIDRO B. SALUSKY, JORGE A. RAMIREZ, WILLIAM OPPENHEIM, BARBARA
More informationSecondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management
Secondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management Complete this course and earn 1 CME POINT Dr. HO Chung Ping MBBS (HK), MRCP, FRCP (Glas, Edin), FHKCP,
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationNew lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments
Nephrol Dial Transplant (2002) 17: Editorial Comments 1731 Nephrol Dial Transplant (2002) 17: 1731 1736 New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological
More informationParicalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients
Pediatr Nephrol (2006) 21:1434 1439 DOI 10.1007/s00467-006-0204-5 ORIGINAL ARTICLE Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients Wacharee Seeherunvong
More informationOriginal Article Long term effects on mineral and bone metabolism by low versus standard calcium dialysate in peritoneal dialysis: a meta-analysis
Int J Clin Exp Med 2015;8(2):2031-2037 www.ijcem.com /ISSN:1940-5901/IJCEM0004376 Original Article Long term effects on mineral and bone metabolism by low versus standard calcium dialysate in peritoneal
More informationCardiovascular Mortality: General Population vs ESRD Dialysis Patients
Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationBONE AND MINERAL METABOLISM in the PD PATIENT
BONE AND MINERAL METABOLISM in the PD PATIENT John Burkart, MD Professor of Medicine/Nephrology Wake Forest University Baptist Medical Center Chief Medical Officer Health Systems Management Maria V. DeVita,
More informationPlasma Serotonin and Markers of Bone Formation and Bone Resorption in Hemodialysis Patients
Dialysis Plasma Serotonin and Markers of Bone Formation and Bone Resorption in Hemodialysis Theodoros Eleftheriadis, 1,2 Georgia Antoniadi, 1 Vassilios Liakopoulos, 1 Theodora Sparopoulou, 2 Ioannis Stefanidis,
More informationChanges in serum osteocalcin levels in the follow-up of kidney transplantation
Original Article Ann Clin Biochem 1997; 34: 651--655 Changes in serum osteocalcin levels in the follow-up of kidney transplantation M R Bonnin", M T Gonzalez-, J M GriIi6 2, J M Cruzado", J Bover-, J M
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationA calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication
Kidney International, Vol. 53 (1998), pp. 223 227 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication JOHN E. ANTONSEN, DONALD
More informationSetting the standard
SCLEROSTIN in NEPHROLOGY MOST REFERENCED OPTIMIZED FOR CLINICAL SAMPLES Setting the standard for clinical research. SCLEROSTIN A BONE-RELATED PROTEIN URINE PROTOCOL AVAILABLE Sclerostin ELISA - Assay Characteristics
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Effect on mortality of elective parathyroid surgery in one hundred and three patients with chronic kidney disease : our experience. White Rose Research Online URL for this
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More information